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Abstract
Despite recent advances in the treatment of metastatic castration-
resistant prostate cancer (mCRPC), agents that provide durable dis-
ease control and long-term survival are still needed. It is a fact that a
tumor-induced immunosuppressive status (mediated by aberrant acti-
vation of inhibitory immune checkpoint pathways as a mechanism to
evade host immune surveillance) plays a crucial role in the pathogen-
esis of cancer, including prostate cancer (PC), making CRPC patients
suitable candidates for immunotherapy. Therefore, growing interest of
anticancer research aims at blocking immune checkpoints (mainly
targeting CTLA-4 and PD1/PD-L1 pathways) to restore and enhance
cellular-mediated antitumor immunity and achieve durable tumor
regression. In this review, we describe the current knowledge regard-
ing the role of immune checkpoints in mediating PC progression,
focusing on CTLA-4 and PD1 pathways. We also provide current clinical
data available, an update on ongoing trials of immune checkpoint
inhibitors in PC. Finally, we discuss the necessity to identify prognos-
tic and predictive biomarkers of immune activity, and we analyze new
immune checkpoints with a role as promising targets for PC therapy.
Introduction
Prostate cancer (PC) is the second most commonly diagnosed
malignant tumor in men and a major cause of mortality, with an esti-
mated 385,560 deaths globally expected in 2020.1 In the last few years,
the identification and the approval of several agents for the treatment
of metastatic castration-resistant prostate cancer (mCRPC), including
cytotoxic drugs (cabazitaxel),2 second-generation anti-androgen com-
pounds (abiraterone acetate and enzalutamide)3-6 and particles emit-
ting radionuclides (radium-223),7 has rapidly changed the therapeutic
armamentarium and the natural history of this disease, prolonging
survival and maintaining patients’ life quality. Despite these progress-
es, mCRPC remains a disease with a lethal outcome that still requires
new treatments to provide durable disease control and to improve
patients’ outcomes. Several therapeutic strategies are currently under
investigation; anticancer immunotherapy is becoming significantly
relevant also in PC. In particular, increasing the host’s immune
response against PC cells could represent a valid and promising ther-
apeutic approach. 
Tumor development and progression result from a cancer-induced
immunosuppressive status, in which the patient’s immune system is
not able to recognize and destroy neoplastic cell clones because cancer
cells are able to elude the anti-tumor immune response (cancer immu-
noediting), hence becoming resistant to immune surveillance.
Immune evasion is therefore recognized as a hallmark feature of can-
cer.8,9 Among different mechanisms involved in cancer immune
escape, immune checkpoints have a key role. Immune checkpoint
pathways [including mainly two immunomodulatory receptors
expressed on T-cells - cytotoxic T lymphocyte antigen-4 (CTLA-4) and
programmed death-1 (PD-1) - and their corresponding ligands - B7-
1/B7-2 and PD-L1, respectively] physiologically dampen T-cell activity,
being crucial for minimizing inflammatory-dependent tissue damage
and maintaining self-tolerance. Cancer cells can over-express specific
immune-checkpoint molecules, negatively regulating the immune sys-
tem. Therefore, the activation of different inhibitory immune check-
point pathways is a fundamental mechanism for the tumor cells’
immune resistance, especially against T-cells.10 In recent years anti-
cancer research focuses on immunotherapy, which aims at enhance
antitumor immunity by blocking immune checkpoints. Monoclonal
antibodies (mAbs) directed against CTLA-4 (ipilimumab) or PD-1/PD-
L1 (i.e., nivolumab, pembrolizumab, atezolizumab) can stimulate the
immune system, reactivating T-cell proliferation and activity. This effi-
cient strategy of checkpoint blockade represents one of the main onco-
logical breakthroughs, with remarkable clinical durable responses and
survival advantages observed in several cancer types.11
To date, sipuleucel-T (an autologous cellular immunotherapy) is the
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only approved immunotherapy for PC patients.12 However, the funda-
mental role of the patient’s immune system in prostate cancerogenesis
has led to further investigate several novel immunotherapeutic mole-
cules, including vaccines (active immunotherapy) and immune check-
point inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1 mAbs), both alone
or in combination with chemotherapy, androgen ablation or radiother-
apy.13 We focused on the role of immune checkpoints (mainly CTLA-4
and PD1 pathways) in PC, with particular attention on the biological
rationale, current clinical studies and future therapeutic perspectives.
Immunosystem in prostate gland
A strong immune rational supports the development of immunother-
apy for PC. The lack of afferent lymphatics and the immunosuppressive
properties of seminal fluid confer to the prostate gland an immunolog-
ically privileged status. Biologically, the majority of prostate tumors
behave like a slow-growing disease, allowing time for a clinically rele-
vant immune response and thus justifying the high immunogenicity of
this tumor.14,15 PC cells, in fact, show an abnormal over-expression of
several highly immunogenic tumor-associated antigens that represent
potential target for immunotherapeutic approaches.16-18
Moreover, PC tissue is marked by a large inflammatory infiltrate of
T-cells [tumor infiltrating lymphocytes (TILs)] within the tumor and in
the surrounded microenvironment.19 Both the innate and the adaptive
branches of the immune system participate in host defense mecha-
nisms against neoplastic prostate cells.20 Macrophages/antigen-pre-
senting cells (APCs), CD8+ cytotoxic T lymphocytes, CD4+ helper T
lymphocytes, and natural killer (NK) cells should recognize and destroy
cancer cells. Therefore, dense TILs infiltration seems to have a positive
prognostic value, correlating with longer patient survival.21 Moreover,
high grade prostatic adenocarcinomas have significantly less infiltra-
tion of T-cells as compared to benign nodular prostatic hyperplasia,22
underscoring that tumor progression could be associated with defects
in cell-mediated immune responses. 
The inability to mount an efficient immune response that restricts
cancer progression is partially due to the presence of non-active effec-
tor TILs [lacking markers of functional activity like perforin or gamma-
interferon (IFNg)],23 and regulatory T-cells (Tregs) within the inflam-
matory infiltrate of PC tissue. Tregs is a small subpopulation of
CD4+/CD25+ and CD8+/Foxp3 T lymphocytes with suppressive func-
tions on the anti-immune response [directly via cell-cell contact or
indirectly by secreting anti-inflammatory cytokines, like interleukin-10
(IL-10) or tumor growth factor (TGFb)],24,25 supposed to have a nega-
tive prognostic role in PC patients,26,27 highlighting that blockage of
these cells may stimulate the generation of effective CD8+ T-cell
immune responses and therefore induce beneficial clinical respons-
es.28,29 In the end, hormonal therapies commonly used for PC treatment
have immunomodulatory effects. Indeed, anti-androgens can activate
thymic regeneration and promote thymopoiesis30 and B-cell prolifera-
tion,31 reduce intratumoral infiltration of immunosuppressive Tregs,
mitigate tolerance to prostatic antigens,32 increase NK cell infiltrate,20
and induce high levels of T-cell infiltration (mainly CD4+ cells) within
PC tissue,20,33 suggesting the potential role of combining immunother-
apy with hormonal agents to enhance anticancer immune-based treat-
ments.34
Cytotoxic T-lymphocyte-associated antigen-4
CTLA-4 is a co-inhibitory receptor expressed on activated T CD4+
and CD8+ lymphocytes, which constrains T-cells activation by binding
to B7-1 (CD80) and B7-2 (CD86) costimulatory molecules expressed on
APCs more avidly than CD28 receptor (the main receptor required for
T-lymphocytes activation).35,36 CTLA-4 is also constitutively expressed
on Tregs where it mediates their immune suppressive effects.37 These
evidences suggested that CTLA-4 blockage could result in broad
enhancement of antitumor immune responses, leading to the develop-
ment of mAbs that specifically inhibit CTLA-4. 
Ipilimumab
Ipilimumab is a fully human immunoglobulin G1 (IgG1) monoclonal
antibody that blocks the activity of CTLA-4, enhancing the immune
response in terms of T-cell activation. It is approved for the treatment
of advanced melanoma and it is currently under investigation in vari-
ous cancer types, including mCRPC. 
Ipilimumab has been evaluated at different doses, schedules and
combinations in mCRPC patients. Preclinical and clinical studies sug-
gested that radiotherapy might cause immune-mediated tumor death
and might induce tumor regression at locations far from the original
site of irradiation (the abscopal effect) in an immune-mediated
process.38 More interestingly, the combination of ipilimumab and con-
ventional anticancer therapies results in a synergic antitumor activi-
ty,39-42 supporting the hypothesis that tumor antigens released during
radiation-induced cell death may enhance the antitumor activity of ipil-
imumab. Based on this evidence, a phase I/II, non-randomized trial
(CA184-107) of ipilimumab given alone or in combination with exter-
nal-beam radiotherapy was performed in mCRPC patients who received
no more than one prior chemotherapy, leading to prostate-specific anti-
gen (PSA) decline in approximately 15% of cases.43 Similar results
derived from a small randomized phase II trial using ipilimumab in
combination with androgen deprivation therapy (ADT) versus ADT
alone in advanced PC patients (undetectable PSA levels rate at 3
months of 55% versus 38%, respectively),44 encouraging further evalu-
ation in this context. A further improvement in biochemical tumor
response rate up to 25-50% has been described with combination of
ipilimumab with granulocyte-macrophage colony-stimulating factor or
vaccines, without worsening ipilimumab-related side effects.45-48
Conversely, data from a small trial ipilimumab assessing in combina-
tion with a single dose of docetaxel versus ipilimumab alone failed to
demonstrate a benefit from the addition of chemotherapy.49
Subsequently, a phase III randomized clinical trial (CA184-043) of a
single dose of bone-directed radiotherapy followed by either ipilimum-
ab at the dose of 10 mg/kg or placebo every 3 weeks for up to four cycles
in CRPC patients with at least one bone metastasis who have pro-
gressed after docetaxel treatment, were performed.50 Although the pri-
mary end point of overall survival (OS) was not met, ipilimumab was
associated with improved progression-free survival [4 months with
ipilimumab versus 3.1 months with placebo; hazard ratio (HR) 0.70;
P<0.0001] and in PSA response (13.1% versus 5.2%). Moreover, data
from pre specified and post hoc subgroup analysis suggested that ipili-
mumab might provide an OS benefit (modified OS 22.7 versus 15.8
months; HR 0.62, P=0038) for patients with a better prognostic profile
(i.e., no visceral metastases, alkaline phosphatase <1.5 times the
upper limit of the normal range and hemoglobin ≥11 g/dL), particularly
for those without visceral metastases, supporting further evaluation of
ipilimumab in patients with a lower disease burden. The most common
grade 3-4 immune-related adverse events were diarrhea (16% in the
ipilimumab group versus 2% in the placebo group), fatigue (11 versus
9%), anemia (10 versus 11%) and colitis (5 versus 0%). Finally, it is
important to underline that patients receiving ipilimumab seem to
report delayed benefit in OS: whereas short-term OS did not differ
between the ipilimumab and placebo arms, survival curves began to
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diverge after 5 months. This data suggest that continuing survival fol-
low-up is warranted to draw strong conclusions and that the length of
follow-up is fundamental to assess the sustainability of survival benefit
of immune checkpoint inhibitors in mCRPC patients. Therefore,
despite the benefit of ipilimumab in the post-docetaxel population was
limited, its use in mCRPC should not be necessarily precluded until a
better definition of the population to treat.51
Currently, new trials with ipilimumab alone or in combination are
ongoing, including a phase III study in chemotherapy-naïve PC (CA184-
095 - NCT01057810) and neoadjuvant settings (NCT01194271). Since
immunotherapy will be more effective in the early stages of disease, a
significant OS benefit might be expected in these settings.52
Tremelimumab
Tremelimumab is a fully human IgG2 monoclonal antibody specific
for CTLA-4, which is also undergoing clinical investigation in PC, in
neoadjuvant and in recurrent disease. A phase I dose-escalation trial in
PSA-recurrent PC demonstrated a prolongation in PSA doubling time in
3 of 11 patients several months after completing treatment with treme-
limumab in combination with short-term ADT, with dose-limiting toxi-
cities including grade G3 diarrhea and skin rash.53 The identification
of delayed and prolonged decline in serum PSA suggests future explo-
ration of this combination in patients with high risk for recurrence, so
as to delay metastatic disease progression.
Tables 138-44,47 and 2 summarize the completed phase I-III clinical tri-
als and the selected ongoing studies of CTLA-4 inhibitors in PC, respec-
tively.
Characteristically, anti-CTLA-4 clinical responses show a slow and
delayed (up to 6 months after treatment initiation) onset’s kinetic,
with pseudo-progression (due to increased immune cell infiltration
rather than a real disease progression) that should be hypothesized
and recognized by clinicians for an adequate disease management.
Programmed death-1/programmed death ligand 1 pathway
The PD-1/PD-L1 pathway has a crucial role in the regulation of T-cell
activity during inflammatory processes. PD-1 is a transmembrane gly-
coprotein T-cell co-inhibitory receptor, expressed on activated CD4+
and CD8+ T-cells, B-lymphocytes, NK cells, and monocytes within 24 h
from immune system activation by various cytokines (including IL-2,
IL-7, IL-15 and IL-21) to mediate immunosuppression by limiting the
immune cells lytic activity.54 In contrast to CTLA-4 that inhibits T-cells
activation during the priming phase of T-cell activation, PD-1 exerts its
                                Review
Table 1. Completed phase I-III clinical trials of CTLA-4 inhibitors alone or in combination with other agents in metastatic castration-resistant
prostate cancer.
Study agent                                 Reference                   Sample size (n)      Key studies                                                 Results
Ipilimumab with or without RT          Slovin et al., 201338                            71                       A phase I/II study to assess safety of                     PSA decline >50%: 16%
[CA184-107]                                                                                                                                       ipilimumab alone or with RT in patients 
                                                                                                                                                             with mCRPC with or without prior 
                                                                                                                                                             chemotherapy                                                              
Ipilimumab with ADT                            Tollefson et al., 201339                     108                      A randomized, phase II study comparing              Patients receiving ipilimumab 
                                                                                                                                                             a single dose of ipilimumab with ADT                   with ADT were more likely to 
                                                                                                                                                             versus ADT alone in patients with mCRPC            have undetectable PSA levels by
                                                                                                                                                                                                                                                      3 months (55 versus 38%)
Ipilimumab with or without                Small et al., 200643                             43                       A randomized, phase II study comparing              Co-administration of docetaxel
docetaxel                                                                                                                                            ipilimumab alone or with docetaxel                       did not enhance activity of
                                                                                                                                                             in chemotherapy-naïve patients                             ipilimumab
                                                                                                                                                             with mCRPC                                                                  
Ipilimumab following RT                      Kwon et al., 201444                            799                      A randomized, phase III trial comparing              The primary end point was not 
[CA184-043]                                                                                                                                     ipilimumab versus placebo following                      met [OS: 11.2 versus 10 months; 
                                                                                                                                                             RT in patients with mCRPC previously                  HR 0.85; P=0.053]
                                                                                                                                                             treated with docetaxel                                               Improvement PFS [4 versus 3.1 
                                                                                                                                                                                                                                                      months; HR 0.70; P<0.0001] 
                                                                                                                                                                                                                                                      and in PSA response [13.1 
                                                                                                                                                                                                                                                      versus 5.2%]
Ipilimumab with PROSTVAC                Madan et al., 201240                                      30                       A phase I dose-escalation trial assessing             PSA level decrease: 58% 
                                                                    Jochems et al., 201441                                                  safety/tolerability of ipilimumab with                    and 
                                                                                                                                                             PROSTVAC in patients with mCRPC                       PSA decline >50%: 25%
Ipilimumab with GVAX                          Van den Eertwegh et al., 201242     28                       A phase I dose-escalation trial using                    PSA decline >50%: 25%
                                                                                                                                                             one GVAX priming dose combined 
                                                                                                                                                             with ipilimumab in patients with mCRPC              
Ipilimumab with GM-CSF                      Fong et al., 200943                              24                       A phase I dose-escalation trial assessing            PSA decline >50%: 50%
                                                                                                                                                             safety/tolerability of ipilimumab with 
                                                                                                                                                             a fixed dose of GM-CSF                                             
Tremelimumab with ADT                      McNeel et al., 201247                         11                       A phase I dose-escalation trial assessing            No significant increase in PSA
                                                                                                                                                             safety/tolerability of tremelimumab                      doubling time
                                                                                                                                                             in combination with bicalutamide                           
RT, radiotherapy; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen; ADT, androgen deprivation therapy; OS, overall survival; HR, hazard ratio; PFS, progression-free survival; GM-
CSF, granulocyte-macrophage colony-stimulating factor.
inhibitory activity during the effector phase of T-cell activation in
peripheral tissues and tumor microenvironment. Therefore, PD-1
receptor acts as a negative checkpoint regulator, preventing T-cells
activation. The interaction between PD-1 and its major ligand PD-L1
(also called B7-H1 or CD274 - the predominant mediator of immuno-
suppression) leads to inactivation of effector molecules (i.e., Syk in B-
cells and Zap70 in T-cells), and inhibition of T-cells proliferation, thus
limiting the inflammatory damage of surrounding tissues. Moreover,
PD-1/PD-L1 interaction prevents autoimmunity by promoting CD4+ T-
cell differentiation into Treg.55,56
The PD-1/PD-L1 axis strongly contributes to tumor development and
progression, representing a mechanism letting tumors to escape from
the host’s immune system. PD-L1 is over-expressed in cancer cells,
stromal cells and TILs of the tumor microenvironment, supporting
tumor immune evasion.57 In addiction, PD-1 is usually expressed at
high levels on tumor-infiltrating Treg, enhancing their proliferation
after ligand binding and promoting tumor growth by dampening the
immune system.
Therefore, the blockade of PD-1/PD-L1 pathway (via mAbs against
PD-1 or PD-L1) may reinforce anti-tumor immune response by stimu-
lating the activity of effector T-cells against cancer cells and tumor
microenvironment and diminishing the suppressive activity of intratu-
moral Treg.10,58 The strength of this biological rationale has been con-
firmed with the outstanding results achieved in the clinical setting
with monoclonal antibodies that disrupt the PD-1/PD-L1 interaction
(i.e., nivolumab, pembrolizumab, atezolizumab). Significant prolonga-
tion of survival, impressive long-lasting responses, and relevant
improvements in clinical outcomes with PD-1/PD-L1 inhibitors has
been observed in different solid tumors [including melanoma,59,60 non-
small-cell lung cancer,61,62 renal-cell carcinoma]63 in the last years.
Our attention is now facing two major pressing clinical issues: the
first one, in the context of cancer with proven efficacy of anti-PD-1/PD-
L1, the identification of predictive markers that enables to identify the
tumor subpopulation most likely to benefit from the therapy; the second
one , the search for other types of cancers (mainly at high mutation
load) in which immunotherapy with checkpoint inhibitors could radi-
cally change the patient’s prognosis. 
As concern the potential predictors of response to anti-PD-1 pathway,
tumor PD-L1 expression, frequently linked with lymphocytes PD-1
expression, has been postulated as the single factor most closely asso-
ciated to aggressive tumor behavior and anti-PD1 blockade response.64-
66 However, the conflicting results overturn the prognostic significance
of tumor PD-L1 expression and its role as a predictor of treatment
response.67-69 Certainly, the lack of a unique and validated method to
evaluate the PD-1/PD-L1 expression, as well as the absence of a pre-
specified score system to assess PD-1/PD-L1 positivity, can (at least
partially) contribute to the lack of conclusive data.
Recently, efforts are directed to assess the role of PD-1/PD-L1 axis in
PC, so as to support the potential development of therapies targeting
this signaling pathway in setting. 
As well as for other tumor types, evidence regarding the expression
of PD-L1 on tumor cells is heterogeneous and contradictory also in PC. 
Taube and colleagues showed a strong association between the
immunohistochemical PD-L1 expression and the likelihood of response
to PD-1 blockade in a cohort of different malignancies. However, the
negative PD-L1 staining of the small subgroup of CRPC samples (only
2 patients) included in this analysis, did not allow to draw definitive
conclusions.64,66 A rare PD-L1 expression from primary prostate tumors
has been recently reported. Interestingly, PC PD-L1 expression seems
to be independent from PTEN loss (whereas several studies have sug-
gested that PTEN loss induces PD-L1 up-regulation as a mechanism of
innate immune resistance), therefore assuming a role of adaptive
immune resistance in mitigating antitumor immune responses.70
Conversely, we reported a relevant percentage of PC cells PD-L1
expression (50%-19% were scored 2+) and TIL PD-1 expression (56%-
19% scored as 2+) in a series of 16 CRPC patients.71
Accordingly, a high expression of PD-1 has been demonstrated in
CD8+ prostate-infiltrating T lymphocytes (thus unable to mount an
effective immune response).72 Moreover, recently Gevensleben and
Colleagues for the first time extensively evaluated the expression of
PD-L1 on primary radical prostatectomy specimens (n=873 samples)
from hormone-treatment-naïve patients using a newly validated mAb
against PD-L1 (clone EPR1161(2)) and a semi-quantitative scoring
system of staining intensity. This study showed an elevated PD-L1
expression (52.2 and 61.7% in the two cohorts analyzed, respectively)
in PC samples, with a correlation between PD-L1 expression and Ki-67
proliferation marker, androgen receptor expression, and significantly
shorter biochemical-recurrence free survival (regardless of tumor
stage, PSA levels, Gleason score and surgical margins).73 The poor
prognostic role of PD-L1 expression confirms the capacity of PD-L1 to
promote tumor recurrence by exhausting antitumor immunity.
Noteworthy, CRPC patients resistant to enzalutamide displayed
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Table 2. Selected ongoing studies of CTLA-4 alone and in combination in prostate cancer (www.clinicaltrials.gov).
Study agent   Phase      Description                         Primary             Patient population          Clinical Trial gov ID        Trial status
                                                                                    endpoints                                                                                              (sample size)
Ipilimumab            III             Ipilimumab versus placebo         OS                             Chemotherapy-nave               NCT01057810                              Completed 
[CA184-095]                                                                                                                         mCRPC patients                                                                              (602 patients)
Ipilimumab             II             Ipilimumab 3 mg/kg versus        Radiological            Chemotherapy-na ve               NCT02279862                              Active, not recruiting 
                                                  ipilimumab 10 mg/kg                    PFS                            mCRPC patients                                                                              (50 patients)
Ipilimumab             II             Ipilimumab plus leuprolide       Immunological       Patients with prostate            NCT01194271                              Completed 
                                                  acetate                                            variables                 cancer before radical                                                                   (19 patients)
                                                                                                             measurements       prostatectomy
                                                                                                                                              (neoadjuvant setting)             
Ipilimumab            II             Ipilimumab plus leuprolide       PSA response         Chemotherapy-naϊve              NCT01377389                              Active, not recruiting 
plus ADT                                   or goserelin or degaralix                                               mCRPC patients                                                                              (48 patients)
Ipilimumab           I/II            Ipilimumab plus AA plus PDN    PFS and safety        Chemotherapy- and                NCT01688492                              Active, not recruiting
plus AA                                                                                                                                  immunotherapy-naϊve                                                                  (50 patients)
                                                                                                                                               mCRPC patients                       
Ipilimumab             I              Ipilimumab following                   Immunological       Chemotherapy-naϊve              NCT01832870                              Active, not recruiting 
and sipuleucel-T                    sipuleucel-T                                  variables                 mCRPC patients                                                                             (9 patients)
                                                                                                             measurements
OS, overall survival; mCRPC, metastatic castration-resistant prostate cancer; PFS, progression-free survival; ADT, androgen deprivation therapy; AA, abiraterone acetate; PDN, prednisone.
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increased levels of PD-L1 positive dendritic cells circulating in blood.
Moreover, the mechanisms that mediate CRPC enzalutamide-resis-
tance might depend on both intrinsic and induced expression of PD-L1
from DCs. The tumor intrinsic PD-L1 expression in enzalutamide-
resistant CRPC did not show classical androgen receptor (AR) activa-
tion, suggesting a PD-L1-driven (but not non-AR dependent) resistance
to enzalutamide.74 In addition, important data suggest the pivotal func-
tion of PC microenvironment in negatively modulating the immune
system response against cancer cells. Clusters of FOXP3+, PD-1+, and
B7-H1+ lymphocytes (implicated in the inhibition and exhaustion of T-
cells) have been detected nearby PC lesions, thereby contributing to
ineffective anticancer immune responses.24 Moreover, tumor-associate
stromal myofibroblasts substantially contribute to an immunosuppres-
sive status of the PC microenvironment by releasing several stromal
factors (CCL2, IL-6, TGFb) that induce monocyte differentiation into
dendritic cells (DCs) with an immunosuppressive phenotype (CD14+,
PD-L1+ DCs).75 Therefore, targeting tumor-associated stromal cells
could represent a promising strategy to strengthen anticancer immune
system. As regards the activity of molecules that disrupt the PD1/PD-L1
interaction in PC patients, data are widely immature. In the large
phase I trial testing the safety and activity of the anti-PD1 antibody
nivolumab in a cohort of 296 patients with advanced solid tumors, no
objective responses were described in the small subgroup of 17 mCRPC
patients (one patient had a 28% reduction in measurable lesions). Two
of the 17 mCRCP tissue specimens were eligible for immunohisto-
chemical analysis, both of which were negative for PD-L1 expression.76
Obviously this sample size is considerably too small (17 cases of CRPC
and only 2 PC samples worthy to immunohistochemical analysis) to
support or rule out further investigations on the role of anti- PD-1/PD-
L1 molecules for PC treatment. Several trials are currently evaluating
the activity of targeting the PD-1/PD-L1 pathway. A Phase 1b, dose-
escalation ongoing study of nivolumab (MDX-1106) aims at determin-
ing the safety and effectiveness of this anti-PD-1 agent in patients with
certain types of cancer, including PC (NCT00730639).
An interesting biomarker-driven phase 2 trial of combined PD-1 and
CTLA-4 blockade in AR-V7 positive metastatic CRPC (mCRPC) patients
is testing the association of nivolumab and ipilimumab in this specific
subset of patients (NCT02601014).
The anti-PD1 antibody pembrolizumab is under evaluation as single
agent in mCRPC patients previously treated with enzalutamide
(NCT02312557), in combination with pTVG-HP plasmid DNA vaccine in
mCRPC patients (NCT02499835), in association with cryosurgery in
treating patients with newly diagnosed, oligo-metastatic PC
(NCT02489357), and combined with ADXS31-142 (a Listeria monocyto-
genes/PSA [Lm-LLO-PSA] vaccine [ADXS-PSA]) in pre-treated mCRPC
patients (NCT02325557). CT-011, an anti–PD-1 antibody, is being
assessed in a phase II trial in combination with sipuleucel-T and low-
dose cyclophosphamide in advanced CRPC patients (NCT01420965).
Several issues need to be clarified to guide a more rational targeted
therapy strategy: if prostate cancer PD-L1 expression be considered a
poor prognostic marker and/or a predictive marker of response to anti-
PD-L1 therapy; if ADT down-regulates steadily tumor PD-L1 expression,
and therefore if it is more appropriate to address an anti-PD-1 therapy
for a disease naïve to hormone therapies or whether on the contrary to
an advanced castration resistant disease assuming the activation of
PD-1/PD-L1 pathway as a mechanism to escape ADT.
Other immune checkpoint molecules - potentialtargets for inhibition
The impressive improvements in immunology have led to the identi-
fication of immune checkpoint proteins others than CTLA-4 and PD-
1/PD-L1, expressed on T cells (and aberrantly on cancer cells) that trig-
ger inhibitory pathways dampening T-cell activity.
Developing molecules that inhibit immune checkpoint proteins, thus
enhancing the anti-tumor immunity, represents one of the main anti-
cancer challenges.B7 proteins
The B7 family includes proteins that interact with known or still
unknown receptors to regulate T lymphocyte activation and function.  
While the interaction between B7-1 (CD80) and B7-2 (CD86) cos-
timulatory ligands (expressed on APC) with CD28 (expressed on T lym-
phocytes) is well known to result in enhanced T-cell activation, and the
B7-H1 (PD-L1)/PD1 interaction dampens T-cells activity, the precise
role of the other B7 ligands (B7-H2, B7-H3, B7-H4, V-domain Ig sup-
pressor of T cell activation [VISTA], and B7-H6) is far from being inti-
mately understood.77
As regards B7-H3 and B7-H4, although many issues remain unre-
solved (identification of the receptor to which they bind, the physiolog-
ical role of B7-H3 - immune-stimulatory or immune-suppressive), it
appears that both of these molecules are implicated in immune-modu-
latory processes of the tumor microenvironment favoring cancer devel-
opment.78B7-H3
B7-H3 (also termed CD276) is a type I transmembrane protein, pref-
erentially expressed on recently activated monocytes, T cells, B cells,
and NK cells. The receptor(s) for B7-H3 has not yet been identified, and
analogously B7-H3 functions are far from being conclusively under-
stood. In fact, B7-H3 has been described to have opposite immune-mod-
ulatory functions (both stimulatory and inhibitory) depending on the
different receptor that it binds. The stimulatory role of B7-H3 consists
in promoting T-cell proliferation and IFN-g expression, while the
inhibitory functions depend on the B7-H3-mediated inhibition of
cytokine production, impairment of type I T-helper cell responses, and
restriction of NK-mediated cytolysis.77,79
Over-expression of B7-H3 has been reported in several tumor types,
with an interesting association to more aggressive tumor biology (low
count of tumor infiltrating lymphocytes, high tumor grade and stage,
metastatic spreading).79-82
PC expresses aberrant levels of B7-H3.78,80,83,84 PC cell surface B7-H3
expression is known to correlate with aggressive histopathologic fea-
tures (larger tumor volume, extra-prostatic extension, seminal vesicle
infiltration, higher Gleason score),83,85 proliferation markers,85
increased risk of tumor recurrence and progression,83,85,86 disease
spread and poor clinical outcomes.78,80
Interestingly, B7-H3 acts in stimulating tumor progression both via
its immune-regulatory properties (blockade of Treg proliferative activ-
ity leading to tumor evasion of the immune system) and through a
direct pro-oncogenic role (altered tumor cells interactions with adhe-
sion molecules, resulting in enhanced tumor cells migration and inva-
siveness, and increased Tem-mediated vascularization).84,86 Moreover,
B7-H3 is expressed also in bone metastases and hormone-resistant PC
specimens, and remains stable during ADT.87 Therefore, the poor prog-
nostic role of B7-H3 along with its expression independent from hor-
monal regulation support B7-H3 as a promising therapeutic target
(also during or after ADT).
B7-H4
B7-H4 (also known as B7S1, B7×, and Vtcn1) is a type I transmem-
brane protein, whose receptor is still undetermined, expressed on acti-
vated APCs and on cancer cells, where it exerts co-inhibitory functions
impairing T-cells proliferation and IL-2 production and constraining the
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expansion of neutrophil progenitors.61,77
The over-expression of B7-H4 has been directly implicated in cancer
cells growth. The tumor expression of this T-cell co-inhibitory ligand,
able to induce immunosuppression, thereby facilitating cancer pro-
gression, has been related with more aggressive cancer behavior (high
tumor burden, advanced tumor stage, increased neo-angiogenesis) and
poor clinical outcome in different tumors.88-92
An immunohistochemical analysis of B7-H4 expression revealed a
diffusely positive cytoplasm and/or membrane staining in PC tissue
compared to healthy prostate tissue, with a positive correlation with
higher tumor grade.93
However, an interesting analysis of B7-H3 and B7-H4 expression in
a murine model of spontaneous PC, although confirming the B7-H3 and
B7-H4 role as biomarkers of PC (significantly elevated expression and
association with cancer progression), yet it highlighted the absence of
a significant impact of B7-H4 in tumor development. In fact, mice lack-
ing B7-H3 showed a dramatic PC progression, while tumor growth was
independent from B7-H4 expression.94TIM 3
T cell immunoglobulin domain and mucin domain-containing mole-
cule 3 (TIM3) is a recently discovered negative immunomodulatory
molecule, preferentially expressed on differentiated T-helper 1 (Th1)
CD4+ T lymphocytes (but not on Th2 cells). The interaction between
TIM3 (the receptor) and its ligand (galectin-9) causes negative regula-
tion of Th1 immunity (inhibition of Th1 and Th17 responses), induc-
tion of peripheral tolerance, and phagocytosis of apoptotic cells.95 TIM3
stimulates cancer progression, maintaining the tumor immunosup-
pressive microenvironment status by inducing T cell exhaustion.
Indeed, recent evidences have shown an over-expression of TIM3 on
CD4+ and CD8+ T cells in different cancer types (including NSCLC,
melanoma, and ovarian patients),96-98 suggesting its role as a potential
therapeutic target for stimulate anti-cancer immune response. Piao
and Colleagues reported an elevated expression of TIM3 on both CD4+
T and CD8+ T cells also in peripheral blood as well as within tumor tis-
sue specimens of PC patients, with a robust correlation with advanced
disease stage (Gleason score, PSA levels, metastatic spread) and poor
prognosis patients.99 In preclinical models, blockade of both PD-1 and
TIM3 enhanced antitumor immune responses, supporting TIM3 as a
new potential target for therapy.
Conclusions
In conclusion, PC represents an interesting setting for the develop-
ment of immune checkpoint inhibitors, considered the intrinsic
immune-stimulating properties of this tumor and the immune-modu-
lating activities of conventional PC treatments (especially ADT).
Future goals aim to delineate the precise setting of treatment (adju-
vant, metastatic hormone-naïve disease, mCRPC), to investigate
potential synergistic effect of combinations with other therapies (hor-
monal agents, chemotherapy, radiotherapy, other immunotherapies),
to outline the proper therapeutic algorithm, and to develop a biomarker
driven therapy that reserves immune checkpoint inhibitors only to
those patients with high probability of response. 
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